However, a significant proportion of patients with HR+/HER2-breast cancer develop resistance to ET, and to address this clinical challenge, researchers have begun to identify new therapeutic targets and drugs, leading to the emergence of cyclin-dependent kinase (CDK) 4/6 inhibitors.4 Here, ERBB2 is linked to breast cancer.